<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00619840</url>
  </required_header>
  <id_info>
    <org_study_id>6520-9979-06</org_study_id>
    <nct_id>NCT00619840</nct_id>
  </id_info>
  <brief_title>Placebo-Controlled Multi-Centre Double-Blind Trial for Adults With Extended-Release Methylphenidate for ADHD</brief_title>
  <acronym>EMMA</acronym>
  <official_title>Placebo-Controlled Multi-Centre Double-Blind Trial for Adults With Extended-Release Methylphenidate for ADHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medice Arzneimittel Pütter GmbH &amp; Co KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medice Arzneimittel Pütter GmbH &amp; Co KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of efficacy and tolerability of extended-release MPD in adults with ADHD,
      compared with a placebo, and to acquire knowledge through long-term observation of adults
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>German validated version of the WRAADDS: Wender-Reimherr-Interview (WRI)</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CAARS self report: long version (CAARS-S:L)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">363</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylphenidate hydrochloride</intervention_name>
    <description>sustained release, 10 mg capsule 1-3 capsules twice daily according to an individual titration schedule</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Medikinet retard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10 mg capsule 1-3 capsules twice daily according to an individual titration schedule</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient treated as outpatient or inpatient

          -  Patient has a good command of German

          -  Score of 85 or greater in the IQ test (MWT-B)

          -  Diagnosis of ADHD according to ADHD-CL (DSM IV) and WRI-WRAADDS &gt; 28 points

          -  ADHD symptoms have existed since childhood (WURS-k &gt;= 30)

          -  Body mass index &gt;= 20

          -  Willing to eat breakfast

          -  Patient is willing and able to come to the observation appointments

          -  Written consent of the patient to participate in the study

        Exclusion Criteria:

          -  Treatment with psychostimulants in the past 2 weeks

          -  Inconsistencies in the CAARS- S:L &gt;= 8 (Inconsistency Index)

          -  Shift work or night work

          -  Alcohol, medication or drug dependency in the past 6 months or manifest drug abuse

          -  Diagnosis of a psychosis (SKID-I)

          -  Epileptic attacks in the past

          -  EEG results which suggest epilepsy

          -  Clinically relevant liver disease

          -  Clinically relevant hyperthyroidism (relevantly elevated TSH, T4)

          -  Acute depressive episode according to ICD-10 F32.2 and ICD-10 32.3 (SKID-I)

          -  Illnesses with schizophrenic symptoms (SKID-I)

          -  Acute manic episode, bipolar disorder (SKID-I)

          -  Diagnosis of a tic disorder

          -  Acute anorexia

          -  Acute prominent panic disorder and generalised anxiety (SKID-I)

          -  Clinically relevant kidney disorders

          -  Known high blood pressure

          -  Known occlusive arterial disease

          -  Known angina pectoris

          -  Known coronary heart disease and state after myocardial infarction

          -  Known tachycardial arrhythmias

          -  Post-stroke status

          -  Known elevated intra-occular pressure

          -  Known enlarged prostates

          -  Participation in a clinical study within the past 30 days

          -  Participation in this study at an earlier point in time

          -  Simultaneous participation in another clinical trial

          -  Women of child-bearing age without adequate contraception

          -  Patients with terminal illness (e.g. cancer)

          -  Pregnancy (positive pregnancy test) or lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Rösler, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Forensic Psychology and Psychiatry, University of Saarland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Forensic Psychology and Psychiatry</name>
      <address>
        <city>Homburg/Saar</city>
        <state>Sarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2008</study_first_submitted>
  <study_first_submitted_qc>February 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <last_update_submitted>February 11, 2008</last_update_submitted>
  <last_update_submitted_qc>February 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Roland Fischer/Head of Medical Dept.</name_title>
    <organization>Medice Arzneimittel Pütter GmbH &amp; Co. KG</organization>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>Attention Deficit Hyperactivity Disorder</keyword>
  <keyword>adult</keyword>
  <keyword>methylphenidate hydrochloride</keyword>
  <keyword>Medikinet retard</keyword>
  <keyword>long-term observation</keyword>
  <keyword>controlled clinical trial</keyword>
  <keyword>safety</keyword>
  <keyword>randomized, double-blind, placebo-controlled trial</keyword>
  <keyword>treatment</keyword>
  <keyword>central nervous system stimulants</keyword>
  <keyword>therapeutic uses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
    <mesh_term>Central Nervous System Stimulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

